Equities

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)50.36
  • Today's Change-0.07 / -0.14%
  • Shares traded1.25m
  • 1 Year change+38.85%
  • Beta0.5746
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

  • Revenue in USD (TTM)522.75m
  • Net income in USD-558.99m
  • Incorporated2011
  • Employees1.28k
  • Location
    Ultragenyx Pharmaceutical Inc60 Leveroni CtNOVATO 94949-5746United StatesUSA
  • Phone+1 (415) 483-8800
  • Fax+1 (415) 483-8810
  • Websitehttps://www.ultragenyx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Edgewise Therapeutics Inc0.00-115.88m3.41bn97.00--6.67-----1.53-1.530.005.450.00----0.00-26.88---27.90--------------0.00-------48.08------
Apogee Therapeutics Inc0.00-118.49m3.57bn91.00--4.48-----2.25-2.250.0013.650.00----0.00-25.44---26.65--------------0.00-------111.10------
Alvotech SA308.73m-618.38m3.83bn999.00------12.39-2.65-2.651.28-2.270.3121.803.66309,038.00-62.49---222.85--48.79---200.30--0.1569-0.23232.04--9.84---7.43------
Immunitybio Inc1.31m-597.65m3.88bn622.00------2,966.13-0.9356-0.93560.0021-1.010.0036--0.492,082.80-162.54-112.76-1,927.61-316.07-----45,701.07-37,700.743.88-2.333.69--159.1767.62-40.00--18.48--
Rhythm Pharmaceuticals Inc112.53m-261.57m4.14bn226.00--368.84--36.77-4.31-4.311.862.490.31361.186.65497,920.30-72.15-47.21-90.85-52.8488.61---230.11-681.383.34--0.417--227.56---1.97---42.10--
TG Therapeutics Inc264.79m-14.36m4.46bn300.00------16.85-0.1067-0.10671.74--------1,002,992.00---62.87---80.0688.32---5.42-405.03---0.0259----8,290.02333.86106.39------
Immunovant Inc0.00-323.01m4.49bn207.00--10.00-----2.21-2.210.003.060.00----0.00-79.97---92.17--------------0.00-------22.93------
Denali Therapeutics Inc0.00-427.49m4.51bn390.00--3.42-----2.76-2.760.009.170.00----0.00-31.77-14.98-33.76-17.71-------104.50----0.0043--204.7420.6755.45--30.70--
Ultragenyx Pharmaceutical Inc522.75m-558.99m4.65bn1.28k--13.40--8.90-6.46-6.466.023.760.37661.916.06409,674.80-40.27-33.35-50.12-38.3086.2593.13-106.93-154.712.65--0.00--19.5253.1814.25--62.91--
Alkermes Plc1.51bn502.58m4.67bn2.10k9.783.618.603.102.951.968.837.990.67881.324.24716,724.3022.671.3428.901.7483.1783.3233.392.123.03--0.18270.0049.618.741,665.99---7.10--
Biohaven Ltd0.00-746.61m5.26bn239.00--12.87-----9.15-9.150.004.160.00----0.00-137.07---176.64--------------0.00------28.43------
Crinetics Pharmaceuticals Inc1.39m-258.54m5.42bn290.00--5.79--3,914.07-3.77-3.770.020110.470.0023--0.41574,775.86-41.16-42.53-44.29-45.36-----18,257.91-5,446.39----0.00---15.2810.57-30.88--34.65--
Arcellx Inc155.82m-40.42m5.54bn130.00--11.52--35.55-0.7196-0.71962.988.950.226----1,198,600.00-5.86-38.82-7.56-45.41-----25.94-339.38----0.022------62.53--113.86--
Krystal Biotech Inc241.52m52.37m5.74bn229.00112.956.4896.6323.771.771.778.2130.800.27251.514.531,054,664.005.91-11.506.33-12.0192.55--21.68-492.857.76--0.00------107.81--39.49--
Data as of Nov 08 2024. Currency figures normalised to Ultragenyx Pharmaceutical Inc's reporting currency: US Dollar USD

Institutional shareholders

42.83%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 20249.65m10.47%
Sands Capital Management LLCas of 30 Jun 20245.35m5.81%
BlackRock Fund Advisorsas of 30 Jun 20244.47m4.85%
Wellington Management Co. LLPas of 30 Jun 20244.44m4.82%
RTW Investments LPas of 30 Jun 20243.26m3.54%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 20242.90m3.15%
SSgA Funds Management, Inc.as of 30 Jun 20242.70m2.93%
ClearBridge Investments LLCas of 30 Jun 20242.35m2.55%
Alkeon Capital Management LLCas of 30 Jun 20242.24m2.43%
Federated Global Investment Management Corp.as of 30 Jun 20242.11m2.29%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.